Catalyst4, Inc.
CIK: 0001900201
Catalyst4, Inc.'s purchase track record
Catalyst4, Inc. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/14/2026 | MPLT | $50.07M | pending | pending | — |
| 7/28/2026 | MPLT | $15.31M | pending | pending | — |
| 10/28/2025 | MPLT | $92.50M | +14.3% | +81.0% | +3.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MPLT | ▲ Buy | Open Market | 4,400,000 | $50.1M | 8/14/2026 | View on chart |
| MPLT | ▲ Buy | Open Market | 1,000,000 | $13.0M | 7/30/2026 | View on chart |
| MPLT | ▲ Buy | Open Market | 3,000 | $38K | 7/29/2026 | View on chart |
| MPLT | ▲ Buy | Open Market | 141,088 | $1.5M | 7/28/2026 | View on chart |
| MPLT | ▲ Buy | Open Market | 65,137 | $761K | 7/28/2026 | View on chart |
| MPLT | ▼ Sell | Other | 14,256,288 | — | 10/28/2025 | View on chart |
| MPLT | ▲ Buy | Open Market | 5,441,176 | $92.5M | 10/28/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.